ClinicalTrials.gg
Not yet recruitingNCT07822503Updated Sep 16, 2026

Laparoscopic vs Open Appendectomy in Obese Patients

An interventional study of Open Appendectomy and Laparoscopic Appendectomy in Acute Appendicitis, Appendicitis (Diagnosis) and Obesity, sponsored by University of Health Sciences Lahore. Not yet recruiting. Open to participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by University of Health Sciences Lahore · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
15 Years to 50 Years
Sex
All
01

Study summary

Acute appendicitis is one of the most common surgical emergencies globally. While surgical removal of the appendix (appendectomy) is the definitive treatment, the optimal surgical approach-laparoscopic versus open-remains widely debated, particularly in obese patients. Obese individuals present unique surgical challenges due to increased abdominal wall thickness, which often necessitates larger skin incisions during open procedures, potentially increasing postoperative pain, wound healing times, and wound complications.

This study aims to compare the postoperative outcomes of laparoscopic appendectomy versus standard open appendectomy in obese patients (BMI ≥ 30 kg/m²) presenting with acute appendicitis. Participants will be randomly assigned to undergo either open appendectomy or laparoscopic appendectomy. The primary outcomes evaluated will be the incidence of surgical site infections (including superficial wound infections and intra-abdominal abscesses) up to 30 days post-procedure and the total length of hospital stay (in days).

02

Conditions studied

  • Acute Appendicitis
  • Appendicitis (Diagnosis)
  • Obesity
03

In context

Appendicitis

419 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

This study's planned enrollment of 166 is above the median of 111 across 252 interventional studies indexed under Appendicitis.

Browse Appendicitis studies →

Lead sponsor

University of Health Sciences Lahore is the lead sponsor of 83 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Obese patients with (BMI) ≥ 30 kg/m².
  2. Clinical diagnosis of acute appendicitis based on Alvarado score (history of right lower quadrant or periumbilical pain shifting to RLQ, nausea and/or vomiting, fever > 38 °C, RLQ guarding and tenderness, and/or leukocytosis > 10,000 cells/mL).
  3. Age between 15 and 50 years.
  4. Both male and female patients.

Exclusion criteria

Exclusion Criteria:

  1. patients (e.g., infection or current therapy).
  2. History of prior chemotherapy, radiotherapy, or recurrent infections.
  3. History of drug or alcohol abuse.
  4. Severe hepatic, renal, or cardiovascular dysfunction.
  5. History of previous abdominal surgery.
  6. Appendicular .
  7. Pregnant women.
  8. Preoperative findings indicating appendiceal perforation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (estimated)

Study arms

  • Active comparator
    Open Appendectomy

    Participants undergo open appendectomy using a standard grid-iron incision under general anesthesia. Appendiceal base ligation and closure are performed in standard anatomical layers.

    Procedure: Open Appendectomy

  • Experimental
    Group 2: Laparoscopic Appendectomy

    Participants undergo laparoscopic appendectomy using a standard 3-port technique (umbilical, left iliac fossa, and lower midline ports) under general anesthesia.

    Procedure: Laparoscopic Appendectomy

Interventions

  • ProcedureOpen Appendectomy

    Open surgical removal of the appendix performed via a standard grid-iron incision under general anesthesia with standard prophylactic antibiotics.

  • ProcedureLaparoscopic Appendectomy

    Laparoscopic surgical removal of the appendix using a standard 3-port configuration (umbilical, left iliac fossa, and lower midline ports) under general anesthesia with standard prophylactic antibiotics.

06

What researchers measure

Primary outcomes

  1. Incidence of Surgical Site Infection (SSI)

    Proportion of patients who develop a surgical site infection, defined as either superficial/deep wound infection (presence of purulent discharge, erythema, localized swelling, or requiring reopening) or intra-abdominal abscess (confirmed via ultrasound in patients presenting with abdominal pain, fever, or fullness)

    Time frame: Up to 30 days postoperatively

  2. Length of Hospital Stay

    The total number of days the patient remained in the hospital postoperatively until meeting discharge criteria (afebrile, tolerating a regular diet, and achieving good pain control).

    Time frame: From day of surgery up to discharge (up to 30 days postoperatively)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07822503
Lead sponsor
University of Health Sciences Lahore
Responsible party
Saira Khan (Principle Investigator, University of Health Sciences Lahore) — Principal investigator
First posted
Sep 16, 2026
Start date
Oct 2, 2026 (estimated)
Primary completion
Apr 2, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion